Global biotechnology company, CSL
(ASX:CSL) has named Dr Brian McNamme as its Chairman elect, in lieu of Professor John Shine’s resignation.
John Shine has been on the board for 11 years with 8 years at the helm.
At the same time, CSL announced its new Chairman elect, Dr Brian McNamme has been appointed a new independent non-executive director with effect from 14 February 2018.
Brian was the company's CEO and MD for 23 years before he retired in 2013.
CSL also appointed the previous Global President of GlaxoSmithKline, Abbas Hussain as a new independent non-executive director, to bring ‘additional biotech insights to the board’ ..
Shares in CSL
(ASX:CSL) are trading 0.38 per cent higher to $141.14
